Key Facts About GSK – A Must-Read for Investors

By Tamara Parker • Monday, February 12 15:36 • Permanent Link

GSK marked a -1.9% change today, compared to -0.0% for the S&P 500. Is it a good value at today's price of $41.12? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
GSK belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 30.21 and an average price to book (P/B) of 4.08
The company's P/B ratio is 12.49
GSK has a trailing 12 month Price to Earnings (P/E) ratio of 13.6 based on its trailing 12 month price to earnings (EPS) of $3.03 per share
Its forward P/E ratio is 9.2, based on its forward earnings per share (EPS) of $4.45
GSK has a Price to Earnings Growth (PEG) ratio of 2.18, which shows the company is overvalued when we factor growth into the price to earnings calculus.
Over the last four years, GSK has averaged free cash flows of $7.86 Billion, which on average grew -0.7%
GSK's gross profit margins have averaged 66.5 % over the last four years and during this time they had a growth rate of 0.1 % and a coefficient of variability of 3.38 %.
GSK has moved 15.7% over the last year compared to 21.5% for the S&P 500 -- a difference of -5.8%
GSK has an average analyst rating of buy and is -4.63% away from its mean target price of $43.11 per share

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.